Cue Health Osake

Cue Health P/B

P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Cue Health (HLTHQ) 11.8.2026 päivämäärällä.

P/B

0,00

YoY

130,37%

Viimeksi päivitetty:

P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Cue Health on 2026 0,00 . P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Cue Health oli 2025 0,00 . Se laskee 130,37% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Cue Health Osakeanalyysi

Mitä Cue Health tekee? Cue Health Inc. is a San Diego-based company specialized in the development and distribution of smart, mobile diagnostic devices. The company was founded in 2010 by Ayub Khattak and Dan Sullivan and has since expanded into various sectors. Cue Health's main business is the development of diagnostic devices that allow end-users to quickly and easily perform diagnostic tests. With a handheld device and proprietary software, customers can perform a wide range of tests in many areas, including tests for flu, colds, inflammatory diseases, sexually transmitted diseases, and COVID-19. Cue Health's business model is based on the idea of providing user-friendliness and portability in the field of diagnostics. With the technology, patients can independently perform diagnostic tests without having to visit a doctor. This not only saves time but also reduces costs for the customer. Since its founding, Cue Health has expanded into several sectors. In addition to the handheld diagnostic device, the company also offers solutions for the healthcare services sector. Through partnerships with biotech companies and medical institutions, the company assists in the development and marketing of diagnostic tests. An important part of Cue Health's history is the development of COVID-19 tests. The company quickly responded to develop a solution for COVID-19 tests that are both safe and easier to use. The Cue COVID-19 Test Kit complies with the requirements of the US Food and Drug Administration and is used in the USA. The test only requires a simple nasal swab, which is then inserted into the handheld device. Within minutes, the user receives the test result. Cue Health intends to continue expanding its technology to offer users a wider range of diagnostic test solutions. The previous tests have shown that the company is capable of delivering innovative solutions to the diagnostics market. The ability to receive fast, accurate, and affordable diagnostic solutions is invaluable for many people, especially those in hard-to-reach locations and without direct access to medical professionals. Overall, Cue Health is a highly innovative company specializing in excellent diagnostic technology and products for the healthcare industry. The products and services of Cue Health have the potential to revolutionize healthcare for all by making diagnostic tests safer, faster, and more convenient. Cue Health on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Cue Health osakkeesta

Eurpoolissa voit löytää P/B (Hinta-kirjanpitoarvo-suhde) Cue Health:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Hinta-kirjanpitoarvo-suhde vertaa yhtiön markkina-arvoa sen kirjanpitoarvoon. Matala P/B voi viitata aliarvostettuun osakkeeseen, kun taas korkea P/B voi osoittaa yliarvostusta tai vahvoja kasvuodotuksia.

P/B = Osakekurssi / Kirjanpitoarvo per osake

Arvioidakseen P/B (Hinta-kirjanpitoarvo-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja P/B (Hinta-kirjanpitoarvo-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata P/B (Hinta-kirjanpitoarvo-suhde):n Cue Health alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Cue Health

Kaikki tunnusluvut — Cue Health